生物活性

• 描述TP-10 is a PDE10A inhibitor with IC50 of 0.8 nM.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01791686	Dense Deposit Disease ... more >> Membranoproliferative Glomerulonephritis Type II C3 Glomerulonephritis Collapse <<	Phase 1	Terminated(Portfolio prioritiz... more >>ation due to slow enrollment and variable spectrum of potential complement abnormalities in DDD patients.) Collapse <<	-	United States, Iowa ... more >> University of Iowa Hospitals & Clinics Iowa City, Iowa, United States, 52242 Collapse <<
  NCT00082121	Myocardial Ischemia ... more >> Coronary Arteriosclerosis Aortic Valve Insufficiency Mitral Valve Insufficiency Collapse <<	Phase 2	Completed	-	United States, California ... more >> San Francisco, California, United States, 94115 United States, District of Columbia Washington, District of Columbia, United States, 20010 United States, Florida Gainesville, Florida, United States, 32610 Orlando, Florida, United States, 32803 Sarasota, Florida, United States, 34239 United States, Georgia Atlanta, Georgia, United States, 30342 United States, Illinois Chicago, Illinois, United States, 60612 United States, Maryland Towson, Maryland, United States, 21204 United States, Massachusetts Boston, Massachusetts, United States, 02118 Springfield, Massachusetts, United States, 01199 United States, Michigan Detroit, Michigan, United States, 48202 Lansing, Michigan, United States, 48910 United States, Ohio Cincinnati, Ohio, United States, 45219 United States, Tennessee Memphis, Tennessee, United States, 38120 United States, Texas Houston, Texas, United States, 77030 United States, Virginia Danville, Virginia, United States, 24541 United States, Wisconsin Madison, Wisconsin, United States, 53792 Milwaukee, Wisconsin, United States, 53215 Collapse <<
  NCT02302755	Dense Deposit Disease	Phase 1	Withdrawn(no recruitment)	-	United States, Iowa ... more >> University of Iowa Health Care Iowa City, Iowa, United States, 52242 Collapse <<

• 参考文献

• [1] Hamaguchi W, Masuda N, et al. Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors. Chem Pharm Bull (Tokyo). 2014;62(12):1200-13.

  [2] Verhoest PR, Chapin DS, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl] -quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem. 2009 Aug 27;52(16):5188-96.